Synairgen (LON:SNG) Shares Down 21.8% – Should You Sell?

Posted by Trent Williams on Mar 13th, 2025

Synairgen plc (LON:SNG – Get Free Report) shares fell 21.8% on Tuesday . The stock traded as low as GBX 1.50 ($0.02) and last traded at GBX 1.56 ($0.02). 1,699,487 shares were traded during trading, an increase of 35% from the average session volume of 1,260,652 shares. The stock had previously closed at GBX 2 ($0.03).

Synairgen Trading Down 9.0 %

The stock’s 50 day moving average price is GBX 2.03 and its 200 day moving average price is GBX 3.34. The company has a market capitalization of £8.36 million, a price-to-earnings ratio of -0.51 and a beta of -2.23.

Synairgen Company Profile

(Get Free Report)

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).